Home LiteratureArticle Details
PMID: 9671388 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.

Oncogene ·Vol. 16 ·No. 24 ·1998-06-18 ·Pages 3097-104

Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmbäck K, Drew AF, Flick MJ, Witte DP, Danø K, Degen JL

Abstract

To investigate the role of plasmin(ogen) in mammary tumor development and progression, plasminogen-deficient mice were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse mammary tumor virus long terminal repeat. Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, bilateral mammary tumors, regardless of the presence or absence of circulating plasminogen. Both the age at which these tumors became palpable and subsequent tumor growth were indistinguishable between plasminogen-deficient mice and plasminogen-expressing littermates. However, plasminogen was found to greatly modify the metastatic potential in this model system; lung metastasis in plasminogen-deficient mice was significantly reduced as compared to littermate controls with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden. Plasminogen activators, as well as other key factors that govern the conversion of plasminogen to plasmin, were expressed within the mammary tumors, suggesting that the plasminogen/plasmin system may promote metastasis by contributing to tumor-associated extracellular proteolysis. The data provide direct evidence that plasmin(ogen) is a tumor progression factor in PymT-induced mammary cancer, and support the hypothesis that hemostatic factors play an important role in tumor biology.

MeSH Terms
Animals Antigens, Polyomavirus Transforming/physiology Base Sequence Blotting, Northern DNA Primers Female Immunohistochemistry In Situ Hybridization Lung Neoplasms/pathology,secondary Mammary Neoplasms, Experimental/etiology,genetics,pathology Mice Mice, Transgenic Plasminogen/genetics Plasminogen Activator Inhibitor 1/genetics Urokinase-Type Plasminogen Activator/genetics
Chemicals
Antigens, Polyomavirus Transforming DNA Primers Plasminogen Activator Inhibitor 1 Plasminogen Urokinase-Type Plasminogen Activator
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Bugge T H
Division of Developmental Biology, Children's Hospital Research Foundation, Cincinnati, Ohio 45229, USA.
Lund L R
Kombrinck K K
Nielsen B S
Holmbäck K
Drew A F
Flick M J
Witte D P
Danø K
Degen J L
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
1998-06-18
Pages
3097-104
Language
English
Region
England
NLM ID
8711562
Subset
IM
Grants
NHLBI NIH HHS · HL47826 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com